Clinical trial NCT05058027: Anti-adhesive Effect and Safety of MEDICURTAIN Applied to Undergoing Thyroid Surgery (Pivotal Study)
Official title: A Randomized, Multicenter, Subject and Assessor Blind, Parallel, Comparative Non-inferiority Clinical Trial Study to Assess the Anti-adhesive Effect and Safety of MEDICURTAIN® Applied to Undergoing Thyroid Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tissue Adhesion, Surgery-Induced
Keywords: Medicurtain®
Medicurtain
Anti-adhesion barrier
Sodium hyaluronate
Lead sponsor: Shin Poong Pharmaceutical Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2021-09-27
Enrollment: 170
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study was designed to demonstrate the non-inferiority of MEDICURTAIN® (investigational device) compared to commercially available GUARDIX-SG® (control device) in treatment of subject who underwent total thyroidectomy for prevention of adhesion formation at 6 weeks after the surgery.

Detailed description: This clinical trial is a randomized, multi center, subject and evaluator blinded, parallel, comparative and non-inferiority clinical trial study to assess the prevention of adhesion formation in the subjects treated either MEDICURTAIN® or GUARDIX-SG at 6 weeks after total thyroidectomy.

The primary endpoint was defined as abnormal findings of esophageal motility evaluated by the independent third evaluator using marshmallow esophagography. The objective of this study was to demonstrate the non-inferiority of investigational device versus control device for adhesion formation at 6 weeks after the administration of investigational or control devices.

Esophageal motility score and clinical symptoms assessed by the independent third evaluator using marshmallow esophagography at 6 weeks after administration of investigational device were secondary outcome.

Eligibility criteria: Inclusion Criteria:

1. The subject (male and female) aged between 20 \~ 65.
2. The subject planned a first thyroidectomy for thyroid disease.
3. The subject did not have medical history of esophagus-related disease
4. The subject was suitable for local anesthesia or general anesthesia (Respiration and Intravenous anesthesia)
5. The subject who could communicate with the investigators fluently, understands the purpose of clinical trial and the risk of participation in the clinical trial, and was willing to comply with guideline for clinical trial.
6. The subject has been informed of the nature of the study (objective, methodology, efficacy, etc.) and signed written informed consent.
7. The subject has been informed the efficacy and risk of anesthesia related to the surgery, procedures and examination, etc. and singed written informed consent.
8. The subject who agrees to comply with permitted contraception during the study (example of permitted contraception: using condom and infertility surgery, etc.)

Exclusion Criteria:

1. The subject had general or local infection.
2. The subject was diagnosed with liver and/or kidney and coagulation abnormalities.
3. The subject took the prohibited concomitant medication.
4. The subject had suppressed immunity or autoimmune disease
5. The subject had hypersensitivity to the investigational devices.
6. The subject was pregnant of a nursing mother or those who plan pregnancy during the study.
7. The subject had serious disease that may affect to the study justified by Investigators (example: heart failure, kidney failure, pancreatitis, and diabetes, etc.)
8. The subjects participate in another investigational study after enrollment of this study or subject previously participated in another investigational study within last 3 months before participating in this study.
9. The subject considered to be not eligible to participate in the study justified by Investigator

Primary outcomes:
measure: Presence of abnormal findings of esophageal motility evaluated by the independent third evaluator using marshmallow esophagography obtained at 6 weeks after administration of investigational device.
timeFrame: Week 6
Secondary outcomes:
measure: Esophageal motility score assessed by the independent third evaluator using marshmallow esophagography obtained at 6 weeks after administration of investigational device
timeFrame: Week 6
measure: Clinical Symptoms assessed using questionnaire by investigator assessed by using 10 point visual analogue scale (VAS).
timeFrame: Follows up to week 6
measure: Clinical Symptoms assessed using questionnaire by subject assessed by using 10 point visual analogue scale (VAS).
timeFrame: Follows up to week 6
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Mokdong Hospital
state: Gangnam-gu, Eonju-ro, 211
Study officials:
affiliation: Ewha Womans University Mokdong Hospital
name: Byung In Moon, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gangnam Severance Hospital
name: Hang-Seok Chang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Korea University
name: Gil Soo Son, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cha University Bundang Cha Hospital
name: Seung Ki Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: